Grants
Interrogating an Argonaute 2 Switch to Regulate Circulating miR-210 and to Coordinate Remote Ischemic Protection
PI: Stephen Chan, MD, PhD
The major goal of this study is to delineate the regulation of release and biologic role of circulating miR-210 in remote ischemic protection.
2014-2017
Defining the Complex Pathobiology of the miR-130/301 Family in Pulmonary Hypertension
PI: Stephen Chan
The major goal of this study is to identify the mechanism(s) of action of the miR-130/301 family in controlling vasoconstriction and vascular stiffness and promoting pulmonary hypertension.
2014-2019
Iron-Sulfur Deficiency is a Critical Pathogenic Lynchpin of Pulmonary Hypertension
NIH/NHLBI 1 R01 HL122596-01A1
PI: Stephen Chan, MD, PhD
The major goal of this study is to identify the microRNA-based control of iron-sulfur cluster expression, mitochondrial metabolism, and pulmonary hypertension.
2015-2020
Induction of Oncogenic microRNA by Rapamycin: Role in TSC Therapy
Co-Investigator: Stephen Chan, MD, PhD (PI: Henske)
The major goal of this study is to delineate the complex molecular actions of rapamycin-dependent microRNA- 21 in TSC tumor development.
2015-2020
Role of MicroRNA in the Pathogenesis and Treatment of TSC
U.S. Army Medical Research Acquisition Activity
Co-Investigator: Stephen Chan, MD, PhD (PI: Henske)
The major goal of this project is to elucidate the mechanisms and consequences of miRNA regulation by mTORC1.
2015-2018
Exercise-induced concentric left ventricular hypertrophy: unrecognized pathology
Co-Investigator: Stephen Chan, MD, PhD (PI: Baggish)
The major goal of this study is to delineate the molecular and physiologic determinants that control exercise- induced concentric left ventricular hypertrophy.
2015-2020
HIPPO signaling in Pulmonary Arterial Hypertension
R01HL130261 (Goncharova)
HIPPO signaling in Pulmonary Arterial Hypertension
Role in grant: PI
2/2016-1/202 NHLBI/NIH/DHHS
The major goal of this study is to determine the role of HIPPO signaling network in PAH pathogenesis and identify new HIPPO-targeting approaches to reverse pulmonary vascular remodeling and PAH.
Antibodies to gremlin 1, activin A and PDGFRβ to target PAVSMC remodeling and pulmonary hypertension
Regeneron (Goncharova/Gladwin/Kass)
Antibodies to gremlin 1, activin A and PDGFRβ to target PAVSMC remodeling and pulmonary hypertension
Role in grant: PI
12/2016-11/2017
Regeneron
The major goal of this study is to evaluate anti-proliferative properties of therapeutic antibodies on pulmonary arterial vascular smooth muscle cell remodeling and pulmonary hypertension.
A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects with Pulmonary Hypertension
Aires Pharmaceuticals, Inc. DRUG
Co-Investigator: Mark Gladwin, MD
2014-2016
Exploring the Genetic, Microbiome, and Environmental Determinants of Pulmonary Hypertension
NIH/NHLBI P01 HL103455
PI: Mark Gladwin, MD
Vascular Subphenotypes of Lung Disease – Project 3
2011-2016
Establishing the Safety and Efficacy of OA-NO2 Therapy in Subjects with Pulmonary Arterial Hypertension and Metabolic Syndrome
NIH/NHLBI P01 HL103455
PI: Mark Gladwin, MD
Vascular Subphenotypes of Lung Disease – Project 2
2011-2016